RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Per Johns Hopkins Case Tracker, global COVID-19 cases are now 1,309,439 with 72,638 fatalities, up 21.7% and 25.2%, respectively, from Friday, April 3. Leaders:
U.S.: 347,003 (+32.7%)/10,225 (+52.6%).
Spain: 135,032 (+14.7%)/13,169 (+20.4%).
Italy: 132,547 (+10.6%)/16,523 (+12.5%).
Germany: 101,178 (+12.6%)/1,662 (+35.1%).
France: 93,785/8,926.
The U.S. rate of new cases remains in a steep upslope although New York may have peaked.
Increases have slowed significantly in Italy and Spain.
China has dropped to #6 in the rankings.
British pound has pared gains vs the USD, while the UK ETF EWU has come off its highs in response to the news of Boris Johnson’s case deteriorating. The Foreign Sec. Dominic Raab has been named as a deputy to the PM
Cresco Labs (OTCQX:CRLBF) has received an adult-use dispensing organization license for its dispensary located at 436 N. Clark Street in River North neighborhood of Chicago.
Sunnyside River North (the “Dispensary”) will soon begin adult-use cannabis sales online. It is company’s sixth retail location in Illinois.
The U.S. Drug Enforcement Agency (DEA) has notified GW Pharmaceuticals (NASDAQ:GWPH) that it no longer considers Epidiolex (cannabidiol) a controlled substance. The change is effective immediately.
The move was expected. In September 2018, the DEA took the intermediate step of categorizing the product as a Schedule 5 drug (includes cough suppressants that contain modest amounts of codeine, Lyrica and Motofen) that have lower abuse potential than Schedule 4 substances (i.e., Xanax, Darvon, Ambien).
Shares up 4% premarket on light volume.
Immunomedics’ (NASDAQ:IMMU) has halted its Phase 3 confirmatory ASCENT study due to compelling evidence of efficacy.
The remarkable results observed across multiple endpoints warranted early discontinuation of the trial.
The study evaluated sacituzumab govitecan in triple-negative breast cancer.
On another note, the company has appointed Harout Semerjian as President and Chief Executive Officer, effective April 16. Most recently, he served as Executive Vice President, Chief Commercial Officer at Ipsen.
Shares are up 118% premarket.
Vir Biotechnology (NASDAQ:VIR) jumps 34% premarket on modest volume in reaction to its collaboration with GlaxoSmithKline (NYSE:GSK) to research and develop treatments for COVID-19.
The partnership will leverage Vir’s proprietary monoclonal antibody platform with GSK’s know-how in functional genomics while combining their respective competencies in CRISPR screening and artificial intelligence (AI) to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research coronavirus vaccines, including SARS-CoV-2.
In addition to gaining access to Vir’s technology, GSK will invest $250M in Vir via the purchase of its common stock at $37.73 per share, a 30% premium to Friday’s close of $29.00.
